What is the trend of prescription outflow after the country's "dual channel" talks about the expansion of national procurement?

Pharmaceutical Network, July 6 News On June 28, Shanghai Sunshine Pharmaceutical Purchasing Network officially announced the results of the fifth batch of national sourcing
.
A total of 148 companies involved 61 selected varieties of national sourcing, with an average price reduction of 56%
.
According to "CCTV News" reports, it is expected that in October this year, patients will be able to use lower-priced drugs
.
The purchase amount of national procurement this time reached 55 billion yuan, a record high since the national procurement, and the speed of national procurement with volume has been significantly accelerated
.
As the first national procurement after the announcement of the "dual-channel" mechanism of the National Talks, such a speed of expansion has to make people wonder: at the moment when the "dual-channel" mechanism of the National Talks is fully implemented and the expansion of the national procurement is accelerating, what are the trends of prescription outflow in the future? ?
01.

It is obvious that the exodus prescription market is expanding
.
First look at the specific changes in the scale of the five batches of national procurement: the first batch of 15.
4 billion yuan, the second batch of 8.
8 billion yuan, the third batch of 22.
6 billion yuan, the fourth batch of 25.
4 billion yuan, and the fifth batch of 55 billion yuan
.
These figures have released at least two signals: First, the scale of national procurement has been further expanded, the products have further increased, and more and more clinical drugs have entered the scope of national procurement; second, the relevant departments are relatively satisfied with the results of national procurement, so Will "push on the accelerator" instead of "push on the brakes
.
" On the other hand, after link profits were squeezed to the greatest extent, Guocai's products changed from the original profit unit of medical institutions to cost units
.
Under this background, the resistance to the outflow of national procurement products from medical institutions to retail terminals will be greatly reduced
.
At the same time, there has been an objective contradiction between the rapid advancement of the national medical insurance negotiations and the "difficulty in entering the hospital" of medical institutions.
The implementation of the "dual channel" mechanism is largely aimed at solving this problem, which has given more and more compliance with the requirements.
Of retail companies have become designated retail organizations and an opportunity to undertake outflow prescriptions
.
With the full implementation of the “dual channel” mechanism of the National Talks, the scale of national procurement is further expanded, and the two major factors are superimposed, and the share of “overflow” to retail terminals will undoubtedly increase further
.

　　02 , the degree of specialization to enhance the
policy interpretation "dual-channel" mechanism introduced in the National Medical Insurance Bureau of designated retail pharmacies made specific requests of information technology, pharmaceuticals management, fund management in three areas, these three areas of the country not just talk about " The requirements of "dual-channel" designated retail institutions also represent to a certain extent the development direction of retail enterprises that will undertake outflow prescriptions in the future
.
In terms of informatization, the information system of designated retail companies must be able to smoothly connect with platforms such as medical insurance and prescription circulation to ensure that the information in each link is comprehensive, accurate, and timely.
This is a big challenge for most retail companies
.
In terms of drug management, it is necessary to equip some drugs with special requirements with special storage and maintenance equipment, as well as sufficient professional pharmacy personnel to reserve and complete prescription drug guidance services.
This is to a large extent different from the OTC drug sales.
The actual situation of the retail terminal
.
Regarding the management of medical insurance funds, designated retail pharmacies are required to have good professional ethics and a sound management system to plug the loopholes in fraudulent insurance and ensure the safety of funds
.
The above three requirements seem simple, but from the current situation of the industry, the retail companies that can really do belong to the echelon of the industry with a relatively high level of management, which forces retail companies that want to intervene in the field of prescription outflow to upgrade and improve their professionalism.
Degree of chemistry
.

　　03.
Social responsibility highlights When it comes
to prescription outflow, many people think that they are sharing the "cake" of the clinical market.
More opportunities for prescription outflow mean more profit opportunities
.
However, if you seriously consider the original intention of the national medical insurance negotiation and mass purchase, you will find that this is actually a de-commercial action
.
If retail pharmacies that sell Guodian and Guocai products can still make a lot of money, it will inevitably run counter to the original intention of the policy.

.
Therefore, retail companies must have reasonable expectations and should not interpret the undertaking of prescription outflows, especially the prescription products from Guotan and Guozai, as simple business behaviors
.
In this process, retail companies are in a sense undertaking the social responsibilities of corporate citizens
.
Of course, this is not to say that undertaking prescription outflows should not be profitable or not profitable.
It is just that you cannot simply calculate economic accounts, but that you have to take a long-term view and calculate big accounts
.

　　04.
The birth of new species.

With the rapid development of the industry, as the reform of the medical and health system continues to deepen, the previously distinct drug supply channels of medical institutions and retail companies have begun to produce more and more intertwining and integration, and the outflow of prescriptions is in this process.
An inevitable product, this product will also produce new changes with changes in external conditions, and new species will appear .
With the further expansion of national sourcing varieties, the scale of prescription outflow is expanding, and its sales are not easy to generate profit.
This part of the business is more to contribute to customer acquisition opportunities and business scale for enterprises that undertake prescription outflow .
However, as a fully market-oriented business unit, the profitability of a retail enterprise is the foundation of survival .
Under this circumstance, a new business model may emerge, combining the prescription outflow with consumer health needs, realizing consumer health management in the true sense, increasing customer loyalty, and tapping greater needs based on family health needs.
Market opportunities .
Perhaps in the near future, the existing classification concepts such as community pharmacies, out-of-hospital pharmacies and DTP pharmacies will become blurred, and it will become increasingly difficult to define the categories of certain companies .
As for the future development of prescription outflow? The answer depends only on whether this development can meet consumers' most practical health needs with higher quality and efficiency .